Drug Profile
Gemopatrilat
Alternative Names: BMS 189921Latest Information Update: 18 Jan 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Antihypertensives; Azepines; Heart failure therapies; Small molecules
- Mechanism of Action ACE inhibitors; Neprilysin inhibitors; Vasopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Hypertension
Most Recent Events
- 18 Jan 2008 Discontinued - Phase-II for Heart failure in USA (unspecified route)
- 18 Jan 2008 Discontinued - Phase-II for Hypertension in USA (unspecified route)
- 09 Mar 2001 BMS 189921 is now called gemopatrilat